* Champions Oncology Inc reported quarterly adjusted earnings of 1 cent per share for the quarter ended in April, higher than the same quarter last year, when the company reported EPS of -19 cents. The lone analyst forecast for the quarter was for a loss of 16 cents per share.
* Revenue rose 7.1% to $14.00 million from a year ago; analysts expected $12.69 million.
* Champions Oncology Inc's reported EPS for the quarter was a loss of 1 cent.
* Champions Oncology Inc shares had fallen by 2.4% this quarter and lost 10.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "hold"
Wall Street's median 12-month price target for Champions Oncology Inc is $6.00 This summary was machine generated from LSEG data July 22 at 09:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Apr. 30 2024 -0.16 0.01 Beat
Jan. 31 2024 -0.06 -0.16 Missed
Oct. 31 2023 -0.17 -0.15 Beat
Jul. 31 2023 -0.11 -0.19 Missed
Comments